عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

Ma’aden, Royal Commission for Jubail and Yanbu Establish Mangrove Park to Preserve Coastal Ecosystems

The agreement was signed by Ma’aden CEO Robert Wilt and Royal Commission for Jubail and Yanbu CEO Mahmood Al Theeb
The agreement was signed by Ma’aden CEO Robert Wilt and Royal Commission for Jubail and Yanbu CEO Mahmood Al Theeb
TT
TT

Ma’aden, Royal Commission for Jubail and Yanbu Establish Mangrove Park to Preserve Coastal Ecosystems

The agreement was signed by Ma’aden CEO Robert Wilt and Royal Commission for Jubail and Yanbu CEO Mahmood Al Theeb
The agreement was signed by Ma’aden CEO Robert Wilt and Royal Commission for Jubail and Yanbu CEO Mahmood Al Theeb

Saudi Arabian Mining Company (Ma’aden) has signed a memorandum of understanding with the Royal Commission for Jubail and Yanbu to establish a mangrove park in the Kingdom, supporting carbon sequestration and biodiversity preservation.

The agreement was signed by Ma’aden CEO Robert Wilt and Royal Commission for Jubail and Yanbu CEO Mahmood Al Theeb, in the presence of Minister of Environment, Water and Agriculture Abdulrahman Al-Fadley, Minister of Industry and Mineral Resources Bandar Alkhorayef, and Deputy Minister for Mining Affairs Khalid Al-Mudaifer at the Saudi Green Initiative (SGI) which took place during the COP28 climate summit in Dubai.

Under the agreement, Ma’aden and the Royal Commission for Jubail and Yanbu will develop a mangrove park and support planting initiatives on Gurmah Island in Jubail, which houses a rich natural mangrove habitat.

The two parties will also cooperate on research initiatives relating to mangrove planting and ecosystem health and will develop local community programs that support ecosystem restoration and improve environmental awareness.

"This partnership is focused on preserving the Kingdom’s unique natural environment. Mangroves provide one of the most effective natural carbon-capture ecosystems and our ability strategy provides a roadmap towards restoring and enhancing the biodiversity of our coastline, in line with Ma’aden’s vision for sustainable growth in Saudi Arabia," Wilt said.

According to Al Theeb, the “partnership with Ma’aden will continue to preserve and expand mangrove ecosystems in Jubail."

“Together we will develop impactful initiatives that benefit the local community and contribute to the Kingdom’s sustainability objectives,” he said.

Ma’aden also launched a dedicated mangrove plantation strategy during SGI that aims to protect existing forests, restore degraded areas and contribute to carbon reduction and biodiversity enhancement. The company has committed to planting 10 million terrestrial trees and 10 million mangroves by 2040, in line with its ambitions as an environmental, social, and governance (ESG) leader to be carbon neutral by 2050.

The strategy supports the Saudi Green Initiative’s target to plant 100 million mangroves in Saudi Arabia by 2030, which will offset around 96 million tons of carbon emissions and help to stabilize the Kingdom’s coastline ecosystems.

Most Viewed

 
 
Varieties

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”